PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells

Toxicology and Applied Pharmacology

Volumn 276, Issue 1, 2014, Pages 73-81

  Rogue, Alexandra ^a,b,c   Anthérieu, Sébastien ^a,b   Vluggens, Aurore ^a,b   Umbdenstock, Thierry ^c   Claude, Nancy ^c   De la Moureyre Spire, Catherine ^c   Weaver, Richard J ^c   Guillouzo, André ^a,b  

^a Univ Rennes   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Fatty acid overload; Fatty acid oxidation; Hepatocytes; Hepatotoxicity; Non alcoholic steatohepatitis

Indexed keywords

BEZAFIBRATE; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; FAT DROPLET; FENOFIBRATE; LIVER X RECEPTOR ALPHA; MURAGLITAZAR; OLEIC ACID; ROSIGLITAZONE; TESAGLITAZAR; TRIACYLGLYCEROL; TROGLITAZONE;

ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION; HEPARG CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID ANALYSIS; LIPID HYDROLYSIS; LIPID VESICLE; LIPOGENESIS; LIVER CELL; RETREATMENT; TREATMENT DURATION; UPREGULATION;

ANIMALIA;

FATTY ACID OVERLOAD; FATTY ACID OXIDATION; HEPATOCYTES; HEPATOTOXICITY; NON-ALCOHOLIC STEATOHEPATITIS;

CELL LINE; DRUG EVALUATION, PRECLINICAL; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; GENE EXPRESSION REGULATION; GLYCINE; HUMANS; LIPID METABOLISM; LIPOGENESIS; LIPOTROPIC AGENTS; LIVER; OLEIC ACID; ORPHAN NUCLEAR RECEPTORS; OXAZOLES; OXIDATION-REDUCTION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; PPAR GAMMA; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRIGLYCERIDES;

EID: 84896034306     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.02.001     Document Type: Article

References (51)

1. Aninat C., Piton A., Glaise D., Le Charpentier T., Langouet S., Morel F., Guguen-Guillouzo C., Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos. 2006, 34:75-83.
2. Antherieu S., Chesne C., Li R., Camus S., Lahoz A., Picazo L., Turpeinen M., Tolonen A., Uusitalo J., Guguen-Guillouzo C., Guillouzo A. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab. Dispos. 2010, 38:516-525.
3. Antherieu S., Rogue A., Fromenty B., Guillouzo A., Robin M.A. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells. Hepatology 2011, 53:1895-1905.
4. Balas B., Belfort R., Harrison S.A., Darland C., Finch J., Schenker S., Gastaldelli A., Cusi K. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J. Hepatol. 2007, 47:565-570.
5. Barish G.D., Narkar V.A., Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J. Clin. Invest. 2006, 116:590-597.
6. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., Balas B., Gastaldelli A., Tio F., Pulcini J., Berria R., Ma J.Z., Dwivedi S., Havranek R., Fincke C., DeFronzo R., Bannayan G.A., Schenker S., Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 2006, 355:2297-2307.
7. Borg J., Klint C., Wierup N., Strom K., Larsson S., Sundler F., Lupi R., Marchetti P., Xu G., Kimmel A., Londos C., Holm C. Perilipin is present in islets of Langerhans and protects against lipotoxicity when overexpressed in the beta-cell line INS-1. Endocrinology 2009, 150:3049-3057.
8. Caldwell S., Argo C. The natural history of non-alcoholic fatty liver disease. Dig. Dis. 2010, 28:162-168.
9. Cerec V., Glaise D., Garnier D., Morosan S., Turlin B., Drenou B., Gripon P., Kremsdorf D., Guguen-Guillouzo C., Corlu A. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 2007, 45:957-967.
10. Chen H., Dardik B., Qiu L., Ren X., Caplan S.L., Burkey B., Boettcher B.R., Gromada J. Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys. Endocrinology 2010, 151:3115-3124.
11. Deehan R., Maerz-Weiss P., Catlett N.L., Steiner G., Wong B., Wright M.B., Blander G., Elliston K.O., Ladd W., Bobadilla M., Mizrahi J., Haefliger C., Edgar A. Comparative transcriptional network modeling of three PPAR-alpha/gamma co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes. PLoS One 2012, 7:e35012.
12. Desvergne B., Michalik L., Wahli W. Transcriptional regulation of metabolism. Physiol. Rev. 2006, 86:465-514.
13. Dong B., Saha P.K., Huang W., Chen W., Abu-Elheiga L.A., Wakil S.J., Stevens R.D., Ilkayeva O., Newgard C.B., Chan L., Moore D.D. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18831-18836.
14. Ericsson H., Hamren B., Bergstrand S., Elebring M., Fryklund L., Heijer M., Ohman K.P. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. Drug Metab. Dispos. 2004, 32:923-929.
15. Fan C.Y., Pan J., Chu R., Lee D., Kluckman K.D., Usuda N., Singh I., Yeldandi A.V., Rao M.S., Maeda N., Reddy J.K. Targeted disruption of the peroxisomal fatty acyl-CoA oxidase gene: generation of a mouse model of pseudoneonatal adrenoleukodystrophy. Ann. N. Y. Acad. Sci. 1996, 804:530-541.
16. Fernandez M., Gastaldelli A., Triplitt C., Hardies J., Casolaro A., Petz R., Tantiwong P., Musi N., Cersosimo E., Ferrannini E., DeFronzo R.A. Metabolic effects of muraglitazar in type 2 diabetic subjects. Diabetes Obes. Metab. 2011, 13:893-902.
17. Fievet C., Fruchart J.C., Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr. Opin. Pharmacol. 2006, 6:606-614.
18. Fisch C., Robin M.A., Letteron P., Fromenty B., Berson A., Renault S., Chachaty C., Pessayre D. Cell-generated nitric oxide inactivates rat hepatocyte mitochondria in vitro but reacts with hemoglobin in vivo. Gastroenterology 1996, 110:210-220.
19. Gavrilova O., Haluzik M., Matsusue K., Cutson J.J., Johnson L., Dietz K.R., Nicol C.J., Vinson C., Gonzalez F.J., Reitman M.L. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 2003, 278:34268-34276.
20. George J., Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol. Pharm. 2008, 5:49-59.
21. Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., Guyomard C., Lucas J., Trepo C., Guguen-Guillouzo C. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15655-15660.
22. Hamren B., Ericsson H., Samuelsson O., Karlsson M.O. Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function-evidence of interconversion. Br. J. Clin. Pharmacol. 2008, 65:855-863.
23. Kane C.D., Francone O.L., Stevens K.A. Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPARalpha. Gene 2006, 380:84-94.
24. Kanebratt K.P., Andersson T.B. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 2008, 36:1444-1452.
25. Kim J.B., Wright H.M., Wright M., Spiegelman B.M. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4333-4337.
26. Laurin J., Lindor K.D., Crippin J.S., Gossard A., Gores G.J., Ludwig J., Rakela J., McGill D.B. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996, 23:1464-1467.
27. Lim H.J., Park J.H., Lee S., Choi H.E., Lee K.S., Park H.Y. PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice. Eur. J. Pharmacol. 2009, 622:45-51.
28. Lomonaco R., Sunny N.E., Bril F., Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 2013, 73:1-14.
29. Mahady S.E., Webster A.C., Walker S., Sanyal A., George J. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis. J. Hepatol. 2011, 55:1383-1390.
30. Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A., Kadowaki T., Lazar M.A., O'Rahilly S., Palmer C.N., Plutzky J., Reddy J.K., Spiegelman B.M., Staels B., Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58:726-741.
31. Miller D.B., Spence J.D. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet. 1998, 34:155-162.
32. Moran-Salvador E., Lopez-Parra M., Garcia-Alonso V., Titos E., Martinez-Clemente M., Gonzalez-Periz A., Lopez-Vicario C., Barak Y., Arroyo V., Claria J. Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J. 2011, 25:2538-2550.
33. Moya M., Gomez-Lechon M.J., Castell J.V., Jover R. Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem. Biol. Interact. 2010, 184:376-387.
34. Musso G., Gambino R., Cassader M., Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52:79-104.
35. Nagai Y., Nishio Y., Nakamura T., Maegawa H., Kikkawa R., Kashiwagi A. Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha. Am. J. Physiol. Endocrinol. Metab. 2002, 282:E1180-E1190.
36. Nagasawa T., Inada Y., Nakano S., Tamura T., Takahashi T., Maruyama K., Yamazaki Y., Kuroda J., Shibata N. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol. 2006, 536:182-191.
37. Ratziu V., Giral P., Jacqueminet S., Charlotte F., Hartemann-Heurtier A., Serfaty L., Podevin P., Lacorte J.M., Bernhardt C., Bruckert E., Grimaldi A., Poynard T. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008, 135:100-110.
38. Reddy J.K., Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 2001, 21:193-230.
39. Rogue A., Lambert C., Josse R., Antherieu S., Spire C., Claude N., Guillouzo A. Comparative gene expression profiles induced by PPARgamma and PPARalpha/gamma agonists in human hepatocytes. PLoS One 2011, 6:e18816.
40. Rubin C.J., Viraswami-Appanna K., Fiedorek F.T. Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes. Diabetes Vasc. Dis. Res. 2009, 6:205-215.
41. Scheen A.J. Pharmacokinetic interactions with thiazolidinediones. Clin. Pharmacokinet. 2007, 46:1-12.
42. Simard J.R., Meshulam T., Pillai B.K., Kirber M.T., Brunaldi K., Xu S., Pilch P.F., Hamilton J.A. Caveolins sequester FA on the cytoplasmic leaflet of the plasma membrane, augment triglyceride formation, and protect cells from lipotoxicity. J. Lipid Res. 2010, 51:914-922.
43. Tanaka T., Yamamoto J., Iwasaki S., Asaba H., Hamura H., Ikeda Y., Watanabe M., Magoori K., Ioka R.X., Tachibana K., Watanabe Y., Uchiyama Y., Sumi K., Iguchi H., Ito S., Doi T., Hamakubo T., Naito M., Auwerx J., Yanagisawa M., Kodama T., Sakai J. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15924-15929.
44. Tonstad S., Retterstol K., Ose L., Ohman K.P., Lindberg M.B., Svensson M. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. Metabolism 2007, 56:1285-1292.
45. Vluggens A., Andreoletti P., Viswakarma N., Jia Y., Matsumoto K., Kulik W., Khan M., Huang J., Guo D., Yu S., Sarkar J., Singh I., Rao M.S., Wanders R.J., Reddy J.K., Cherkaoui-Malki M. Reversal of mouse Acyl-CoA oxidase 1 (ACOX1) null phenotype by human ACOX1b isoform [corrected]. Lab. Invest. 2010, 90:696-708.
46. Wang Y.X., Lee C.H., Tiep S., Yu R.T., Ham J., Kang H., Evans R.M. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159-170.
47. Wang L., Zhang D., Swaminathan A., Xue Y., Cheng P.T., Wu S., Mosqueda-Garcia R., Aurang C., Everett D.W., Humphreys W.G. Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection. Drug Metab. Dispos. 2006, 34:427-439.
48. Watanabe M., Houten S.M., Wang L., Moschetta A., Mangelsdorf D.J., Heyman R.A., Moore D.D., Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 2004, 113:1408-1418.
49. Ye J.M., Frangioudakis G., Iglesias M.A., Furler S.M., Ellis B., Dzamko N., Cooney G.J., Kraegen E.W. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. Endocrinology 2002, 143:4527-4535.
50. Zhang Y., Castellani L.W., Sinal C.J., Gonzalez F.J., Edwards P.A. Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev. 2004, 18:157-169.
51. Zhang B.C., Li W.M., Li X.K., Zhu M.Y., Che W.L., Xu Y.W. Tesaglitazar ameliorates non-alcoholic fatty liver disease and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient mice. Exp. Ther. Med. 2012, 4:987-992.